Miri Halperin Wernli

Dr Miri Halperin Wernli is a senior pharmaceutical and biomedical executive with over 25 years of strategic and operational leadership in the biopharmaceutical industry and a deep understanding of drug and product development. Dr Halperin Wernli has held worldwide senior leadership positions in product development, R&D and Strategic Marketing throughout Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals). Her extensive pharmaceutical industry and biomed research and development experience covers the full spectrum of areas and activities from Pre-clinical to Clinical Development and Strategy, to Drug Registration and Launch, across several Therapeutic Areas. Dr. Halperin Wernli is an experienced pharmaceutical leader with skills and broad expertise in Drug Development, Regulatory Affairs, Project & Portfolio Management, Development Finance & Controlling, and Corporate Strategy and Governance.
Bio last updated 16 Jan 2017

Article Timeline

Network Graph

Displaying all related organisations and their related contacts. Hover over a node to display a link to the BNiQ page for that person or organisation.

Positions - Current

PositionCompanyYearCompany's current rankWA staff
Co-Founder, Chief Executive Officer
Creso Pharma
Creso Pharma

Directors Interests

CompanyDateTransaction typeNumber of sharesPrice per shareTransaction valueNature of change
Creso Pharma21 Aug 2018Issued4,072,950$0.05$203,648Rights issue
Creso Pharma31 Mar 2017Other5,250,000OtherConversion of securities: 1,750,000 - Performance Rights
Creso Pharma31 Mar 2017Issued5,250,000OtherConversion of securities
Source: Morningstar

Equity Capital Markets Deals

DateCompanyTransaction TypeTotal Value
27/03/17Creso PharmaPlacement$8.0m>>


Co-Founder, Chief Executive Officer
Year started and most recent title

Share Transactions

$204k Issued
$0 Other
$0 Issued
Total value as at the date of the transaction
Source: Morningstar

BNiQ Disclaimer